Perspective Therapeutics, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Johan Spoor
- Full Time Employees
- 165
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2401 Elliott Avenue Seattle WA United States of America 98121
- IPO Date
- Nov 10, 2005
- CIK
- 0000728387
- Website
- perspectivetherapeutics.com
- Similar Companies
- Business
- Perspective Therapeutics, Inc. (NYSE American: CATX) develops and commercializes precision targeted alpha therapies (TATs) using proprietary Pb-212-based alpha-particle radiopharmaceuticals for cancer treatment in the United States. The company offers image-guided theranostics leveraging chemically matched Pb-203/Pb-212 isotope pairs conjugated to high-affinity tumor-specific peptides via a proprietary Pb-specific chelator; core pipeline candidates include VMT-α-NET in Phase 1/2a for SSTR2-expressing neuroendocrine tumors, VMT01 in Phase 1/2a for MC1R-positive metastatic melanoma, and earlier-stage programs targeting additional solid tumors such as those expressing melanocortin 1 receptor or somatostatin receptors; complementary imaging diagnostics enable tumor visualization and patient selection prior to alpha therapy delivery; a proprietary 212Pb generator supports isotope supply for clinical trials and commercial-scale production. Founded in 1983 and headquartered in Seattle, Washington, the company operates primarily in the radiopharmaceutical sector with ongoing clinical trials at leading academic institutions and expanding manufacturing capabilities across regional facilities. Recent developments include first patient dosing with [212Pb]VMT01 monotherapy at 1.5 mCi in its Phase 1/2a melanoma study in April 2025; dosing of eight patients into Cohort 3 (6.0 mCi) of the VMT-α-NET study within three months of opening in June 2025; presentation of updated interim Phase 1/2a data for VMT-α-NET at ESMO Congress 2025 showing no dose-limiting toxicities in 55 patients and eight confirmed responses in Cohort 2; cash position of $227 million as of December 31, 2024, bolstered by prior fundraising including an $87.4 million private placement in March 2024, funding operations into late 2026 amid scaling of manufacturing sites acquired recently.
Company News
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX
ADAR1 Capital Management LLC Purchases 654,142 Shares of Perspective Therapeutics, Inc. $CATX
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results